Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials

Focused on U.S. Manufacturing: Witnessing the Full Launch of the "Dual Taiwan-U.S. Production Base" Strategy

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that Taiwan's Representative to the United States Alexander Tah-ray Yui and Mme. Karen Lo, accompanied by Charles Chi Yu Chou, Director General of Taipei Economic and Cultural Office (TECO) Miami, and Felipe Tsai, Deputy Director of TECO Miami, visited PharmaEssentia's Puerto Rico facility on April 20 (Eastern Time). This marks the second high-level visit by a Taiwan government official to PharmaEssentia's overseas operations — following the May 2023 visit by then-Representative Hsiao Bi-khim (now Vice President of Taiwan) to the company's U.S. subsidiary in Boston — underscoring the Taiwan government's strong commitment to supporting the international expansion of Taiwan's biotechnology industry.

The visit also brought together a distinguished group of Puerto Rico officials, including Bernardo Márquez, Mayor of Toa Baja; James Ramos, Economic Development, Director of Toa Baja; Soraya Morón, Deputy Secretary of Strategic Operations, Department of Economic Development and Commerce (DDEC); and Denisse Rodriguez, Invest Puerto Rico’s Stakeholder Affairs Director. The joint presence of representatives from both the Taiwan and Puerto Rico governments reflects strong bilateral support for PharmaEssentia's new facility and demonstrates shared confidence in the company's local investment.

Sam Lin, Head of Global Operations of PharmaEssentia and General Manager of PharmaEssentia Puerto Rico, hosted the delegation on behalf of the company. He presented an overview of PharmaEssentia's corporate development, recent key milestones, investment progress in Puerto Rico, and future operational strategy. The delegation also toured the facility to gain a firsthand look at the construction progress and future development roadmap.

This year, PharmaEssentia has officially launched the full-scale buildout of its new Puerto Rico facility, actively expanding local production capacity as it advances its "Dual Taiwan-U.S. Production Base" strategy to build a more resilient global supply chain. The new Puerto Rico facility represents a critical milestone in the company's global manufacturing footprint, laying a key foundation for future operational growth.

The visit further strengthens the ties between Taiwan's biotechnology industry and Puerto Rico's government and investment community. PharmaEssentia reaffirmed its commitment to bilateral cooperation, leveraging innovative R&D and international manufacturing to enhance Taiwan's biotechnology sector on the global stage.

About PharmaEssentia
PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in hematology, oncology, and immunology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter).